Research programme: Crohn's disease therapy - Deltagen
Alternative Names: Crohn's disease therapy research programme – DeltagenLatest Information Update: 16 Jul 2016
At a glance
- Originator Deltagen
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Crohn's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Crohn's-disease in USA
- 01 Jul 2003 Deltagen has filed a voluntary petition under Chapter 11 of the federal Bankruptcy Code
- 24 Jul 2002 Preclinical trials in Crohn's disease in USA (unspecified route)